gene in people relapsing right after treatment While using the BCL2 antagonist venetoclax. 66 Resistance to those agents has actually been connected to these mutations in about 70% of cases, Despite the fact that they are generally subclonal as well as their distinct role resulting in resistance has to be proven.Genetic susceptibility mechanisms. M